Skip to main content

Table 4 Comparison of quality of life scores between two groups after treatment

From: Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

  ECF group TCF group  
Functioning scores 1 Mean (SD) score Mean (SD) score P3
Physical functioning 69.4 (14.9) 68.3 (19.1) 0.81
Role functioning 69.1 (16.7) 70.8 (21.2) 0.71
Emotional functioning 63.9 (12.5) 64.6 (13.5) 0.82
Cognitive functioning 83. 2 (11.4) 78.1 (13.1) 0.08
Social functioning 65. 8(15.6) 73.7 (15.5) 0.03
Global quality of life 57.6 (15.1) 54.8 (16.3) 0.46
Symptom scores 2    
Fatigue 42.5 (12.7) 44.9 (16.7) 0.48
Nausea and vomiting 19.3 (16.7) 32.4 (26.1) 0.01
Pain 32.8 (17.1) 41.4 (22.6) 0.08
Dyspnoea 7.6 (16.3) 11.1 (21.1) 0.13
Sleep difficulties 25.5 (21.4) 29.4 (22.2) 0.45
Appetite loss 34.4 (24.9) 40.8 (27.7) 0.31
Constipation 13.2 (21.2) 15.7 (25.8) 0.65
Diarrhoea 13.6 (19.9) 9.5 (17.0) 0.35
Financial difficulties 61.4 (25.7) 56.0 (24.8) 0.37
  1. 1 Higher scores show better functioning and global quality of life.
  2. 2 Higher scores indicate greater symptoms.
  3. 3 P values derived from independent samples t-tests.
  4. SD = Standard deviation
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us